Humanwell Healthcare (SHA:600079) subsidiary Yichang Humanwell Pharmaceutical obtained approval from China's drug administrator to conduct clinical trials for esketamine hydrochloride injection.
The trials will focus on treating depression with acute suicidal ideation or behavior, according to a Wednesday filing with the Shanghai bourse.
The pharmaceutical company's shares rose 2% in recent trade.